COMMON VARIABLE IMMUNODEFICIENCY

Common variable immunodeficiency is the most commonly seen primary immune deficiency condition in adults, characterized by impaired B cell differentiation. The patient is diagnosed with common variable immunodeficiency by recurrent bacterial infections usually accompanied by chronic lung diseases, gastrointestinal/liver diseases, granulomatous diseases, autoimmunity, lymphoid hyperplasia, splenomegaly or malignancies. Serum IgG concentration is significantly low along with low IgA and/or IgM concentrations. Intravenous immunoglobulin (IVIG) is the first choice of treatment. Immunoglobulin treatment ameliorates recurrent infections and associated complications such as autoimmune diseases and pulmonary injury. The main cause of death in patients with common variable immunodeficiency is chronic lung diseases or malignancies, because acute bacterial infections is usually prevented by IVIG therapy

DAPSONE-INDUCED METHEMOGLOBINEMIA IN A PATIENT WITH WELLS SYNDROME: A CASE REPORT

Case: A 24 year old woman, was admitted to our outpatient clinic with common urticarial lesions after treatment with amoxicillin clavulanic acid. Lesions were annular, erythematous, indurated plaques with changing diameters.. A relapse was occured after oral methylprednisolone/cetirizine/topical mometasone treatment. After treatment resistance with hydroxychloroquine for 6 weeks, dapsone was started. On the 5th day of 2x100 mg dapsone treatment severe headache, dizziness, palpitations, fatigue, was considered methemoglobinemia: Dapsone induced methemoglobinemia was shown with 5.10 % methemoglobin level and followed up with supportive treatment

THE RELATIONSHIP BETWEEN sTREM-1 AND ACTIVATION OF INFLAMMATORY BOWEL DISEASES

Objective: In inflammatory bowel disease (IBD), there is no reliable biomarker, yet. We aimed to determine whether Serum Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) could be useful as a marker for the diagnosis and/or the determination of disease activity in patients with IBD

Diagnostic and prognostic value of Nesfatin-1 in sepsis and septic shock

Nesfatin-1 is an anorectic protein, and we expect it to decrease during sepsis and septic shock. We aimed to analyze it and determine the relationship between Nesfatin-1 levels and quick Sequential Organ Failure Assessment(qSOFA) score, renal Sequential Organ Failure Assessment (SOFA) score, and mortality in patients with sepsis and septic shock. Sixty-nine hospitalized adult patients diagnosed with sepsis and septic shock in the internal medicine department, were included in the study after approval of the Clinical Research Ethics Committee. Sepsis diagnosis was based on the detected focus of infection, positive blood cultures, and response to antibiotics. Twenty-one healthy controls matched for age and sex with these patients were also included in the study. Sixty-nine septic patients and twenty-one healthy volunteers were included in the study. Nesfatin-1 levels were compared with covariates. Nesfatin-1 levels in septic patients were lower than that of healthy controls. There was no significant difference in Nesfatin-1 between diabetic and non-diabetic subgroups. Patients with quick Sequential Organ Failure Assessment (qSOFA) score of three had a statistically significantly lower Nesfatin-1 level than those of patients with the score of zero, one, and two. Nesfatin-1 was correlated negatively with C reactive protein. We found a statistically significant difference in 1-month mortality between Nesfatin-1 levels below and over 80pg/mL. In order to use Nesfatin-1 as a biomarker in differentiating sepsis from healthy population, more comprehensive and more studies are needed. If supported by new studies, Nesfatin-1 levels below 80 pg / mL at first admission in septic patients may direct the clinician to broad-spectrum antibiotic therapy and earlier intensive care follow-up

HOW DO WE FOLLOW THE GUIDELINES IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES?

Objective: We aimed to retrospectively investigate compliance with guidelines in order to increase the awareness of physicians towards current treatment approaches and goals in Type 2 diabetes mellitus (DM)

Choice of treatment based on Turkish hypertension consensus report: Do we follow the recommendations?

Objective: The aim of this study was to determine how often the recommendations of the Turkish Hypertension Consensus Report are followed, and to draw attention to the report

Serum endotrophin levels in patients with heart failure with reduced and mid-range ejection fraction

Background: Endotrophin, a type VI collagen cleavage product, has fibrosis, and insulin resistance effects. Type VI collagen also plays a role in cardiac fibrosis. In this study, we aimed to investigate the role of endotrophin in the pathogenesis of cardiac fibrosis by determining its levels in patients with heart failure with reduced and mid-range ejection fraction (EF). We also aimed to determine the possible association between endotrophin and treatment that prevents ventricular fibrosis

Serum Adropin Levels Are Reduced in Adult Patients with Nonalcoholic Fatty Liver Disease

Objectives: Adropin is a novel marker of metabolic syndrome and insulin resistance. The aim of this study was to explore the association of serum adropin levels with hepatosteatosis among adult patients. Materials and Methods: Serum biochemical parameters including liver and renal function tests, insulin levels, and serum adropin levels were compared between adult patients with nonalcoholic fatty liver disease (NAFLD) and healthy control cases. Results: A total of 51 patients with a mean age of 37.9 +/- 9.96 years diagnosed with grade 2-3 hepatosteatosis and 30 healthy control cases with a mean age of 34.8 +/- 9.5 years were included in the study. Serum adropin levels in the NAFLD group were statistically significantly lower than in the control cases (588.4 +/- 261.0 vs. 894.2 +/- 301.2, respectively; p < 0.001). The study participants were further subdivided into 2 groups as patients with (n = 35) or without (n = 46) insulin resistance using the serum homeostatic model of assessment-insulin resistance (HOMA-IR). Serum adropin levels were statistically significantly lower in patients with insulin resistance (p < 0.01). There was a negative correlation between adropin levels and serum insulin, HOMA-IR, urea, gamma-glutamyl transferase, total cholesterol, and triglyceride levels. Conclusion: We observed a decrease in serum adropin levels among adult patients with NAFLD. We also found lower levels of serum adropin in patients with insulin resistance, supporting previous data in the literature. Studies investigating the association of adropin levels with other inflammatory parameters are warranted to define its exact role in the pathogenesis of hepatosteatosis. (C) 2019 The Author(s) Published by S. Karger AG, Base